Provided by Tiger Trade Technology Pte. Ltd.

First Trust Nasdaq Pharmaceuticals ETF

41.88
+0.51281.24%
Post-market: 41.980.1040+0.25%16:40 EDT
Volume:72.13K
Turnover:3.02M
Market Cap:1.08B
PE:- -
High:41.91
Open:41.44
Low:41.09
Close:41.37
52wk High:42.87
52wk Low:27.30
Shares:25.75M
Float Shares:25.75M
Volume Ratio:2.49
T/O Rate:0.28%
Dividend:0.42
Dividend Rate:1.01%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Sector Update: Healthcare Stocks Rise Premarket Monday

MT Newswires Live
·
Sep 14

BioMarin Appoints Bristol Myers Squibb Research Chief Robert Plenge to Board

Reuters
·
Sep 14

Press Release: BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors

Dow Jones
·
Sep 14

U.S. Stocks on the MOVE-US Energy Stocks, Baldwin, Johnson & Johnson

Reuters
·
Sep 14

J&J - Jnj Reports Rybrevant Plus Chemotherapy Extends Pfs2 by 10.8 Months in Nsclc

THOMSON REUTERS
·
Sep 14

Johnson & Johnson’s Rybrevant® (Amivantamab-Vmjw) Plus Chemotherapy Delivers Longest Reported Median Overall Survival in Egfr Exon 20 Insertion Mutation-Positive Lung Cancer

THOMSON REUTERS
·
Sep 14

J&J - Jnj Reports no New Safety Signals for Rybrevant Plus Chemotherapy in Nsclc Study

THOMSON REUTERS
·
Sep 14

Potential Buyer Emerges for Johnson & Johnson's Orthopedics Unit

Deep News
·
Sep 14

Perspective Therapeutics Enters Cancer Clinical Trial Collaboration With Merck; Shares Up Pre-Bell

MT Newswires Live
·
Sep 14

Perspective Therapeutics Partners with Merck to Test [212Pb]PSV359 with Keytruda in FAP-Α-Positive Solid Tumors

Reuters
·
Sep 14

Perspective Therapeutics, - Co Sponsors Study; Merck Provides Pembrolizumab at no Cost

THOMSON REUTERS
·
Sep 14

Johnson & Johnson reports PAPILLON study meets primary endpoint

TIPRANKS
·
Sep 14

Market Chatter: Apollo Global in Talks to Buy J&J Orthopedics Unit for $20 Billion

MT Newswires Live
·
Sep 14

One State's Battle to Stop People from Taking Unapproved Weight-Loss Drugs

Dow Jones
·
Sep 14

Nanobiotix announces updated safety, efficacy data from JNJ-1900 study

TIPRANKS
·
Sep 14

Johnson & Johnson Says Lung Cancer Drug Combination Extends Median Survival to Over 34 Months

MT Newswires Live
·
Sep 14

J&J Shares up 1.2% Premarket After Report Co's Orthopedics Unit Draws Apollo Interest in Potential $20 Bln Deal

THOMSON REUTERS
·
Sep 14

Big Pharma is Pouring Billions into China's Biotechs

Dow Jones
·
Sep 14

Dow Jones Top Company Headlines at 1 am ET: Biggest AI Rivals Agree They Need to Slow it Down | Amazon ...

Dow Jones
·
Sep 14

J&J - Rybrevant Plus Chemotherapy Delivers Longest Reported Median Overall Survival in Egfr Exon 20 Insertion Nsclc

THOMSON REUTERS
·
Sep 14